On October 23rd, Chinalink Health-B (06622.HK) announced that the top-line results of the two-year Phase III clinical trial of NVK002 (one of the company's core products) named "China CHAMP" were released. After two years of treatment, the analysis of this study showed statistically significant differences in the main efficacy indicators between the NVK002 eye drop group (0.01% and 0.02% doses) compared to the placebo group. The NVK002 eye drop group outperformed the placebo group and showed a dose-dependent effect. Both doses of NVK002 demonstrated good safety and high patient compliance.

China CHAMP is a randomized, double-blind, placebo-controlled, multicenter, Phase III clinical study with the main objective of evaluating the efficacy and safety of NVK002 (low doses of atropine at 0.01% and 0.02%) in treating myopia progression in Chinese children and adolescents. The trial involved 18 centers and enrolled 777 patients.